Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (80)
October 23, 2006
- Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
- Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
- Maurer's Healthcare Insight (77)
July 24, 2006
- Maurer's Healthcare Insight (76)
June 26, 2006
- Maurer's Healthcare Insight (75)
May 29, 2006
- Maurer's Healthcare Insight (74)
April 10, 2006
- Maurer's Healthcare Insight (73)
March 13, 2006
- Maurer's Healthcare Insight (71)
December 19, 2005
- Maurer's Healthcare Insight (70)
November 28, 2005
- Maurer's Healthcare Insight(69)
November 14, 2005
- Maurer's Healthcare Insight (68)
October 17, 2005
- Maurer's Healthcare Insight (67)
September 26, 2005
- Maurer's Healthcare Insight (66)
August 8, 2005
- Maurer's Healthcare Insight (65)
July 11, 2005
- Maurer's Healthcare Insight (64)
June 13, 2005
- Maurer's Healthcare Insight (63)
May 30, 2005
- Maurer's Healthcare Insight (62)
April 25, 2005
- Maurer's Healthcare Insight (61)
March 28, 2005
- Maurer's Healthcare Insight (60)
March 14, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…